Compounds > indolactam v
Page last updated: 2024-08-26

indolactam v and ER-Negative PR-Negative HER2-Negative Breast Cancer

indolactam v has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Neudörfl, JM; Schmalz, HG; Sperlich, J; Stahn, S; Stein, J; Teusch, N1

Other Studies

1 other study(ies) available for indolactam v and ER-Negative PR-Negative HER2-Negative Breast Cancer

ArticleYear
Synthetic Indolactam V Analogues as Inhibitors of PAR2-Induced Calcium Mobilization in Triple-Negative Breast Cancer Cells.
    ChemMedChem, 2018, 01-22, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Calcium; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Indoles; Lactams; Lyngbya Toxins; Molecular Structure; Protein Kinase C; Receptor, PAR-2; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2018